DE60024108D1 - Leukotrien rezeptor - Google Patents

Leukotrien rezeptor

Info

Publication number
DE60024108D1
DE60024108D1 DE60024108T DE60024108T DE60024108D1 DE 60024108 D1 DE60024108 D1 DE 60024108D1 DE 60024108 T DE60024108 T DE 60024108T DE 60024108 T DE60024108 T DE 60024108T DE 60024108 D1 DE60024108 D1 DE 60024108D1
Authority
DE
Germany
Prior art keywords
receptor
leukotrien
leukotrien receptor
pharmaceutical composition
vasodilation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024108T
Other languages
English (en)
Other versions
DE60024108T2 (de
Inventor
Jun Takasaki
Masazumi Kamohara
Mitsuyuki Matsumoto
Tetsu Saito
Tohru Sugimoto
Toshio Ota
Takao Isogai
Tetsuo Nishikawa
Yuri Kawai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of DE60024108D1 publication Critical patent/DE60024108D1/de
Application granted granted Critical
Publication of DE60024108T2 publication Critical patent/DE60024108T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
DE60024108T 1999-09-14 2000-09-13 Leukotrien rezeptor Expired - Lifetime DE60024108T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25998699 1999-09-14
JP25998699 1999-09-14
PCT/JP2000/006265 WO2001019986A1 (en) 1999-09-14 2000-09-13 Peptide leukotriene receptor

Publications (2)

Publication Number Publication Date
DE60024108D1 true DE60024108D1 (de) 2005-12-22
DE60024108T2 DE60024108T2 (de) 2006-08-03

Family

ID=17341703

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024108T Expired - Lifetime DE60024108T2 (de) 1999-09-14 2000-09-13 Leukotrien rezeptor

Country Status (9)

Country Link
US (2) US6878525B1 (de)
EP (2) EP1213353B1 (de)
JP (1) JP3307922B2 (de)
AT (1) ATE310086T1 (de)
AU (1) AU7312100A (de)
CA (1) CA2375605C (de)
DE (1) DE60024108T2 (de)
ES (1) ES2250185T3 (de)
WO (1) WO2001019986A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059113A2 (en) * 2000-02-08 2001-08-16 Curagen Corporation G-protein coupled receptor proteins and nucleic acids encoding same
GB0003079D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Novel protein
US6586205B1 (en) * 2000-02-11 2003-07-01 Millennium Pharmaceuticals, Inc. 43239 a novel GPCR-like molecule and uses thereof
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
CA2374911A1 (en) * 2000-03-29 2001-10-04 Incyte Genomics, Inc. G-protein coupled receptors
GB0008504D0 (en) * 2000-04-05 2000-05-24 Pfizer Ltd Novel polypeptide
WO2001077149A2 (en) * 2000-04-07 2001-10-18 Bayer Aktiengesellschaft Regulation of human cyslt2-like gpcr protein
US20040071695A1 (en) * 2000-06-06 2004-04-15 Franz-Werner Kluxen Novel g-protein coupled receptor
US7531310B2 (en) 2000-11-17 2009-05-12 Bristol-Myers Squibb Company Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11
JP2006021997A (ja) * 2002-07-09 2006-01-26 Ono Pharmaceut Co Ltd ｃｙｓＬＴ１／ｃｙｓＬＴ２両受容体拮抗性呼吸器疾患治療剤
WO2015061754A2 (en) * 2013-10-25 2015-04-30 Lpath, Inc. COMPOSITIONS AND METHODS FOR BINDING CYSTEINYL LEUKOTRIENES (cysLTs) FOR TREATMENT OF DISEASE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
NZ518662A (en) * 1999-11-17 2004-10-29 Arena Pharm Inc Endogenous and non-endogenous versions of human G protein-coupled receptors
WO2001042269A1 (en) 1999-12-10 2001-06-14 University Of Virginia Patent Foundation Human cysteinyl leukotriene receptor
GB0003079D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Novel protein
US6586205B1 (en) 2000-02-11 2003-07-01 Millennium Pharmaceuticals, Inc. 43239 a novel GPCR-like molecule and uses thereof
US20040071695A1 (en) 2000-06-06 2004-04-15 Franz-Werner Kluxen Novel g-protein coupled receptor

Also Published As

Publication number Publication date
EP1213353B1 (de) 2005-11-16
EP1213353A4 (de) 2003-05-28
US7217800B2 (en) 2007-05-15
CA2375605A1 (en) 2001-03-22
EP1614425A2 (de) 2006-01-11
US6878525B1 (en) 2005-04-12
AU7312100A (en) 2001-04-17
JP3307922B2 (ja) 2002-07-29
CA2375605C (en) 2011-05-10
US20050037968A1 (en) 2005-02-17
ES2250185T3 (es) 2006-04-16
WO2001019986A1 (en) 2001-03-22
DE60024108T2 (de) 2006-08-03
ATE310086T1 (de) 2005-12-15
EP1213353A1 (de) 2002-06-12
EP1614425A3 (de) 2006-01-25

Similar Documents

Publication Publication Date Title
LU91122I2 (fr) Efalizumab et ses dérivés pharmaceutiquement acceptables (raptiva).
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
AU2001264885A1 (en) Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
NO20011721L (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5- reseptoren
PT776324E (pt) Antagonista da endotelina
EE201000020A (et) Ravimkompositsioonid, mis p?hinevad antikolinergiliselt toimivatel henditel ja
DE60118564D1 (de) Propan-1,3-dion-derivate
ZA200004313B (en) Formulation of fast-dissolving efa virenz capsules or tablets using super-disintegrants.
ATE310086T1 (de) Leukotrien rezeptor
TR199501387A2 (tr) Alfa1-adrenerjik reseptör antagonistleri olarak, yeni £3-(4-fenilpiperazin-1-il) propilamino|-piridin, pirimidin ve benzen türevleri.
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
NO20026209D0 (no) Endoparasitticidale midler for frivillig oralt inntak av dyr
IL145684A0 (en) Treatment of pulmonary hypertension
NO951055D0 (no) Galeniske former for forlenget frigivelse av alfuzosinhydroklorid
DK0966299T3 (da) Hidtil ukendte orale formuleringer af calcitonin.
ATE285753T1 (de) Lysin enthaltende kautablette
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
ES2159260B1 (es) Nueva composicion de metanosulfonato de paroxetina
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
MXPA03008051A (es) Nuevas composiciones farmaceuticas a base de anticolinergicos y/o antagonistas del receptor nk1.
US5563157B1 (en) Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
DE60229298D1 (de) Neues kristallines tricyclisches triazolobenzazepinderivat
DE69922918D1 (de) Neuropeptid Y Antagonisten
DE29900238U1 (de) Brennwertbrenner

Legal Events

Date Code Title Description
8364 No opposition during term of opposition